Montelukast Dorom (Montelukast Sodium)

Montelukast Sodium works as a selective antagonist of the cysteinyl leukotriene receptor CysLT1. By blocking this receptor, it prevents leukotrienes from causing bronchoconstriction, mucus production, and inflammation, thereby easing airway obstruction and allergic responses.

The dose of Montelukast Dorom is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Healthcare providers follow approved labeling and clinical guidelines to select an appropriate regimen for each individual.

Safety data for Montelukast Dorom in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare professional.

To order Montelukast Dorom, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and bronchodilators. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control of allergic symptoms, but it does not replace rescue inhalers for acute bronchospasm.

Montelukast Dorom should be stored at temperatures below 25 °C (77 °F). Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Montelukast Dorom is administered orally as a tablet. It can be taken with or without food, typically once daily in the evening, but the exact timing and administration instructions are provided by the prescriber based on individual therapeutic needs.

Serious adverse reactions include severe skin disorders such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, angioedema, and neuropsychiatric events like mood changes, depression, or suicidal thoughts. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Dorom should not be used by individuals with known hypersensitivity to montelukast sodium or any of its excipients. Caution is also advised for patients with severe liver impairment or those taking interacting medications that may alter its effectiveness.